TLRY - US Congressman urges DEA to complete marijuana review reclassify drug
2024-01-05 12:51:13 ET
More on Canopy Growth, Tilray, etc.
- Canopy Growth: Reverse Split Won't Help
- Tilray Has A Well Diversified Business Model (Rating Upgrade)
- Tilray Is Getting High On Share Supply
- Tilray, Canopy face more uncertainty in 2024 as US elections loom
- Canopy Growth falls on share consolidation
For further details see:
US Congressman urges DEA to complete marijuana review, reclassify drug